Literature DB >> 17526905

Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography.

Beat A Kaufmann1, Christopher Lewis, Aris Xie, Ayoub Mirza-Mohd, Jonathan R Lindner.   

Abstract

AIMS: We hypothesized that molecular imaging of endothelial P-selectin expression with targeted myocardial contrast echocardiography (MCE) could identify recently ischaemic myocardium without infarction. METHODS AND
RESULTS: The microvascular behaviour of P-selectin-targeted (MB(p)) and control (MB(c)) microbubbles was assessed by intravital microscopy of the cremaster muscle in mice. Targeted MCE imaging with MB(p) and MB(c) was performed in mice after brief left anterior descending (LAD) occlusion and reperfusion and in open- and closed-chest controls. Regional wall motion and perfusion by MCE were assessed during occlusion and after reperfusion. On intravital microscopy, ischaemia-reperfusion produced a 10-fold increase (P < 0.01) in venular attachment for MB(p). Attachment for MB(c) was rare. With myocardial ischaemia-reperfusion, LAD occlusion produced hypoperfusion and wall motion abnormalities that resolved after 45 min of reperfusion. At 45 min, signal enhancement in the post-ischaemic region was four-fold greater (P < 0.05) for MB(p) vs. MB(c). MB(p) produced low-level enhancement in non-ischaemic myocardium in all open-chest animals, suggesting P-selectin expression from surgical cardiac exposure.
CONCLUSION: Molecular imaging of P-selectin with targeted MCE can identify the presence of recently ischaemic myocardium in the absence of necrosis and after resolution of hypoperfusion and post-ischaemic stunning. This technique can potentially provide a method for risk stratifying patients with acute chest pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17526905     DOI: 10.1093/eurheartj/ehm176

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  54 in total

Review 1.  Molecular imaging with contrast enhanced ultrasound.

Authors:  Scott M Chadderdon; Sanjiv Kaul
Journal:  J Nucl Cardiol       Date:  2010-08       Impact factor: 5.952

Review 2.  The role of cardiac ultrasound in stem cell therapy.

Authors:  Andrew M Kahn; Anthony N Demaria
Journal:  J Cardiovasc Transl Res       Date:  2009-01-22       Impact factor: 4.132

Review 3.  Leveraging the power of ultrasound for therapeutic design and optimization.

Authors:  Charles F Caskey; Xiaowen Hu; Katherine W Ferrara
Journal:  J Control Release       Date:  2011-07-30       Impact factor: 9.776

4.  Molecular imaging of thrombus: technology in evolution.

Authors:  Jonathan R Lindner
Journal:  Circulation       Date:  2012-05-30       Impact factor: 29.690

Review 5.  Ultrasound molecular imaging with targeted microbubble contrast agents.

Authors:  Alexander L Klibanov
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

Review 6.  Molecular imaging of cardiovascular disease with contrast-enhanced ultrasonography.

Authors:  Jonathan R Lindner
Journal:  Nat Rev Cardiol       Date:  2009-06-09       Impact factor: 32.419

Review 7.  Molecular imaging targets of cardiac remodeling.

Authors:  Jamshid Shirani; Vasken Dilsizian
Journal:  Curr Cardiol Rep       Date:  2009-03       Impact factor: 2.931

Review 8.  Contrast ultrasound molecular imaging of inflammation in cardiovascular disease.

Authors:  Jonathan R Lindner
Journal:  Cardiovasc Res       Date:  2009-09-26       Impact factor: 10.787

9.  Ischemic memory imaging in nonhuman primates with echocardiographic molecular imaging of selectin expression.

Authors:  Brian P Davidson; Scott M Chadderdon; J Todd Belcik; Saurabh Gupta; Jonathan R Lindner
Journal:  J Am Soc Echocardiogr       Date:  2014-04-26       Impact factor: 5.251

10.  Ultrasound Molecular Imaging of Inflammation in Mouse Abdominal Aorta.

Authors:  Shiying Wang; Sunil Unnikrishnan; Elizabeth B Herbst; Alexander L Klibanov; Frank William Mauldin; John A Hossack
Journal:  Invest Radiol       Date:  2017-09       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.